The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2024 | Selecting between CAR-Ts and bispecifics for patients with HRMM who are triple-class exposed
Roberto Mina, MD, University of Turin, Turin, Italy, discusses selecting between therapies for patients with high-risk multiple myeloma (HRMM) who are triple-class exposed. He considers access, patient fitness, and disease characteristics when selecting between CAR-Ts and bispecific antibodies. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
